Cryoport (CYRX) 10-K 13 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 01, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	Cryoport, Inc.
Entity Central Index Key	0001124524
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 351,453,000
Trading Symbol	CYRX
Entity Common Stock, Shares Outstanding		30,436,322
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 37,327,125	$ 15,042,189
Short-term investments	9,930,968	0
Accounts receivable, net of allowance for doubtful accounts of $100,000 and $70,000, respectively	3,543,666	1,625,476
Inventories	220,514	114,796
Prepaid expenses and other current assets	752,269	516,427
Total current assets	51,774,542	17,298,888
Property and equipment, net	4,357,498	2,511,174
Intangible assets, net	137,220	90,646
Deposits	350,837	363,403
Total assets	56,620,097	20,264,111
Current Liabilities:
Accounts payable and other accrued expenses	1,709,397	1,203,354
Accrued compensation and related expenses	1,262,478	925,514
Deferred revenue	66,315	73,444
Capital lease obligations	23,191	0
Total current liabilities	3,061,381	2,202,312
Convertible note, net of discount of $288,400	14,711,580	0
Deferred rent liability, net of current portion	267,415	175,033
Capital lease obligations, net of current portion	33,156	0
Total liabilities	18,073,532	2,377,345
Commitments and contingencies
Stockholders' Equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 30,319,038 and 25,701,924 issued and outstanding at December 31, 2018 and 2017, respectively	30,319	25,702
Additional paid-in capital	179,501,577	149,293,947
Accumulated deficit	(140,988,484)	(131,432,883)
Accumulated other comprehensive income	3,153	0
Total stockholders' equity	38,546,565	17,886,766
Total liabilities and stockholders' equity	56,620,097	20,264,111
Class A convertible preferred stock [Member]
Stockholders' Equity:
Preferred stock value	0	0
Class B Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred stock value	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Allowance for doubtful accounts receivable	$ 100,000	$ 70,000
Convertible Subordinated Debt	$ 288,400
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,500,000	2,500,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,319,038	25,701,924
Common stock, shares outstanding	30,319,038	25,701,924
Class A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	800,000	800,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class B Convertible Preferres Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	585,000	585,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 19,626,453	$ 11,954,267
Cost of revenues	9,386,188	5,987,834
Gross margin	10,240,265	5,966,433
Operating costs and expenses:
General and administrative	9,798,793	7,420,837
Sales and marketing	7,245,644	5,232,406
Engineering and development	1,840,443	1,205,692
Total operating costs and expenses	18,884,880	13,858,935
Loss from operations	(8,644,615)	(7,892,502)
Other income (expense):
Interest expense	(69,253)	(15,693)
Warrant inducement and repricing expense	(899,410)	0
Other income, net	77,631	14,337
Total other expense, net	(891,032)	(1,356)
Loss before provision for income taxes	(9,535,647)	(7,893,858)
Provision for income taxes	(19,954)	(5,143)
Net loss	$ (9,555,601)	$ (7,899,001)
Net loss per share – basic and diluted	$ (0.34)	$ (0.34)
Weighted average common shares outstanding - basic and diluted	28,210,648	22,963,382

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net loss	$ (9,555,601)	$ (7,899,001)
Other comprehensive income, net of tax:
Net unrealized gain on available-for-sale debt securities	23,582	0
Foreign currency translation adjustments	(20,429)	0
Other comprehensive income	3,153	0
Total comprehensive loss	$ (9,552,448)	$ (7,899,001)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Class A Preferred Stock	Class B Preferred Stock	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2016	$ 5,680,402	$ 0	$ 0	$ 17,604	$ 129,196,680	$ (123,533,882)	$ 0
Balance (in shares) at Dec. 31, 2016				17,604,283
Net loss	(7,899,001)	0	0	$ 0	0	(7,899,001)	0
Other comprehensive income, net of taxes	0
Stock-based compensation expense	3,477,781	0	0	0	3,477,781	0	0
Proceeds from ATM, net of costs of $44,202	0
Issuance of common stock for board of director compensation	70,000	0	0	$ 16	69,984	0	0
Issuance of common stock for board of director compensation (in shares)				15,872
Proceeds from common stock offering, net of costs of $170,326	11,405,924	0	0	$ 6,325	11,399,599	0	0
Proceeds from common stock offering, net of costs of $170,326 (in shares)				6,325,000
Proceeds from exercise of stock options and warrants	5,151,660	0	0	$ 1,757	5,149,903	0	0
Proceeds from exercise of stock options and warrants (in shares)				1,756,769
Balance at Dec. 31, 2017	17,886,766	0	0	$ 25,702	149,293,947	(131,432,883)	0
Balance (in shares) at Dec. 31, 2017				25,701,924
Net loss	(9,555,601)	0	0	$ 0	0	(9,555,601)	0
Other comprehensive income, net of taxes	3,153	0	0	0	0	0	3,153
Stock-based compensation expense	5,408,625	0	0	0	5,408,625	0	0
Warrant repricing expense	899,410	0	0	0	899,410	0	0
Proceeds from tender offer, net of costs of $99,357	4,641,807	0	0	$ 1,580	4,640,227	0	0
Proceeds from tender offer, net of costs of $99,357 (in shares)				1,580,388
Proceeds from ATM, net of costs of $44,202	3,363,156	0	0	$ 248	3,362,908	0	0
Proceeds from ATM, net of costs of $44,202 (in shares)				248,839
Issuance of common stock, net of costs of $191,670	$ 9,808,330	0	0	$ 1,000	9,807,330	0	0
Issuance of common stock, net of costs of $191,670 (in shares)	248,839			1,000,000
Issuance of common stock for board of director compensation	$ 70,000	0	0	$ 6	69,994	0	0
Issuance of common stock for board of director compensation (in shares)				6,228
Proceeds from exercise of stock options and warrants	6,020,919	0	0	$ 1,783	6,019,136	0	0
Proceeds from exercise of stock options and warrants (in shares)				1,781,659
Balance at Dec. 31, 2018	$ 38,546,565	$ 0	$ 0	$ 30,319	$ 179,501,577	$ (140,988,484)	$ 3,153
Balance (in shares) at Dec. 31, 2018				30,319,038

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2018USD ($)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 191,670
ATM [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	44,202
Tender Offer [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 99,357

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net loss	$ (9,555,601)	$ (7,899,001)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	857,939	664,831
Amortization of debt discount and deferred financing costs	0	6,130
Unrealized loss on short-term equity securities	16,233	0
Stock-based compensation expense to employees, directors and consultants	5,478,625	3,547,781
Warrant inducement and repricing expense	899,410	0
Loss on disposal of property and equipment	397,467	186,030
Provision for bad debt	40,215	11,646
Changes in operating assets and liabilities:
Accounts receivable	(1,958,405)	(441,643)
Inventories	(105,718)	(25,297)
Prepaid expenses and other current assets	(235,825)	(261,489)
Deposits	12,576	0
Accounts payable and other accrued expenses	405,074	123,249
Accrued compensation and related expenses	336,736	506,480
Deferred revenue	(7,129)	0
Accrued interest	66,023	(1,843)
Net cash used in operating activities	(3,352,380)	(3,583,126)
Cash Flows From Investing Activities:
Purchases of property and equipment	(2,914,029)	(1,714,931)
Purchases of short-term investments	(9,923,619)	0
Patent and trademark costs	(46,574)	(85,646)
Net cash used in investing activities	(12,884,222)	(1,800,577)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options and warrants	6,020,919	5,151,660
Proceeds from issuance of convertible debt	15,000,000	0
Proceeds from issuance of common stock, net of costs	9,808,330	0
Proceeds from February 2018 tender offer, net of offering costs	4,641,807	0
Proceeds from the ATM, net of offering costs	3,363,156	0
Payment of deferred financing costs	(288,420)	0
Repayment of capital lease obligation	(14,700)	0
Proceeds from public offering, net of offering costs	0	11,405,924
Repayment of related-party notes payable	0	(656,221)
Net cash provided by financing activities	38,531,092	15,901,363
Effect of exchange rate changes on cash and cash equivalents	(9,554)	0
Net change in cash and cash equivalents	22,284,936	10,517,660
Cash and cash equivalents - beginning of year	15,042,189	4,524,529
Cash and cash equivalents - end of year	37,327,125	15,042,189
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	637	4,744
Cash paid for income taxes	19,954	5,143
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Net unrealized gain on available-for-sale debt securities	23,582	0
Leasehold improvements paid by tenant allowance	127,316	0
Purchase of equipment through capital lease obligations	71,047	0
Deferred offering costs in connection with future warrant repricing included in accounts payable and prepaid expenses and other current assets	$ 0	$ 31,981

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Note 1. Nature of the Business Cryoport, Inc. (“Cryoport”) is the premier provider of temperature controlled logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions to the biopharma, reproductive medicine and animal health markets to ship, store and deliver biologic materials, such as immunotherapies, stem cells, CAR-T cell therapies, vaccines and reproductive cells for clients worldwide Cryoport actively supports pharmaceutical and biotechnology companies, points-of-care, contract research organizations, central laboratories, contract manufacturers, university researchers and other entities service the life sciences industry. The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiaries, Cryoport Systems, Inc., Cryoport Netherlands B.V. and Cryoport UK Limited (collectively, the “Company”). All intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable. Short-Term Investments Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings. Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity. Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, capital lease obligations and the convertible note. The carrying value for all such instruments, except capital lease obligations and the convertible note, approximates fair value at December 31, 2018 and 2017 due to their short-term nature. The carrying value of capital lease obligations approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. The convertible note bears an interest rate that fluctuates with the changes in LIBOR and, because the variable interest rates approximate market borrowing rates available to us, we believe the $14.7 million carrying value of the convertible note approximates its fair value at December 31, 2018. Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2018 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments. Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer. Customers The Company grants credit to customers within the U.S. and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for a limited number of established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2018, and 2017 are net of reserves for doubtful accounts of $100,000 and $70,000, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates. The Company’s customers are in the biotechnology, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, whic h is subject to normal credit risk. As of December 31, 2018, there were two customers that accounted for 29.0% and 23.4%, respectively, of net accounts receivable. There was no other single customer that owed us more than 10% of net accounts receivable at December 31, 2018 and 2017. The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the years ended December 31, 2018 and 2017, the Company had revenues from foreign customers of approximately $1.7 million and $1.3 million, respectively, which constituted approximately 9.0% and 11.1%, respectively, of total revenues. There was one customer that accounted for 18.2% of revenues during the year ended December 31, 2018. No other single customer generated over 10% of revenues during the years ended December 31, 2018 and 2017. Inventories The Company’s inventories consist of packaging materials and accessories that are sold to customers. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors. Property and Equipment The Company provides shipping containers (“Shippers”) to its customers and charges a fee in exchange for the use of the Shipper. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the Shipper over a period of time. The Company retains the title to the Shippers and provides its customers the use of the Shipper for a specific shipping cycle. At the culmination of the customer’s shipping cycle, the Shipper is returned to the Company. As a result, the Company classifies the Shippers as property and equipment for the per-use Shipper program. Property and equipment are recorded at cost. Shippers and data loggers, which comprise 34% and 47% of the Company’s net property and equipment balance at December 31, 2018 and 2017, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations. Capitalized Software Capitalized software, which is included in property and equipment, net, consists of costs to develop internal use software, which the Company uses to provide various services to customers. The costs are capitalized from the time that the preliminary project stage is completed and considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Once this software is ready for use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is generally 7 years. Capitalized software is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If an impairment indicator is present, a recoverability analysis is performed based on estimated undiscounted cash flows to be generated form the software in the future. If the analysis indicates that the carrying value is not recoverable from future cash flows, the software cost is written down to the estimated fair value and an impairment is recognized. These estimates are subject to revision as market conditions and the Company’s assessments change. Intangible Assets Intangible assets are comprised of patents and trademarks. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. Long-lived Assets If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2018. Deferred Financing Costs Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method, and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings. Income Taxes The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ” ASC 740. As of December 31, 2018 and 2017, there were no unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s provision for income taxes consists of state minimum taxes. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at December 31, 2018 and 2017, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2018 and 2017. The Company is subject to taxation in the U.S., various state jurisdictions, and in the Netherlands. As of December 31, 2018, the Company is no longer subject to U.S. federal examinations for years before 2015 and for California franchise and income tax examinations for years before 2014. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions. Revenue Recognition See Note 13. Engineering and Development Expenses Expenditures relating to engineering and development are expensed in the period incurred. Stock-Based Compensation The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. The Company accounts for forfeitures of unvested awards as they occur. The Company’s stock-based compensation plans are discussed further in Note 12. Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values at each of those interim financial reporting dates. Basic and Diluted Net Income (Loss) Per Share We calculate basic and diluted net income (loss) per share using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed dividends and cumulative preferred stock dividends (if any), whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. The following shows the amounts used in computing net loss per share for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 Net loss $ (9,555,601 ) $ (7,899,001 ) Weighted average common shares outstanding – basic and diluted 28,210,648 22,963,382 Basic and diluted net loss per share $ (0.34 ) $ (0.34 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Years Ended December 31, 2018 2017 Stock Options 3,130,635 4,582,383 Warrants 1,329,594 4,579,699 Convertible Note 1,372,998 — 5,833,227 9,162,082 Segment Reporting We currently operate in one reportable segment and the chief operating decision maker is our Chief Executive Officer. Foreign Currency Transactions Management has determined that the functional currency of its subsidiaries is the local currency. Assets and liabilities of the Netherlands and UK subsidiaries are translated into U.S. dollars at the period-end exchange rates. Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity. The translation gain (loss) adjustment totaled $(20,400) for the year ended December 31, 2018. Comprehensive Income (Loss) Comprehensive income includes all changes in equity (net assets) during a period from non-owner sources. For the year ended December 31, 2018, the components of comprehensive income (loss) consist of unrealized gains on available-for-sale debt securities and foreign currency translation losses. For the year ended December 31, 2017, net loss equaled comprehensive loss as there were no items of comprehensive loss. Off Balance Sheet Arrangements We do not currently have any off balance sheet arrangements. Reclassifications Certain prior year amounts have been reclassified in the consolidated balance sheets to conform to the current year presentation. Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting” which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, “Compensation-Stock Compensation ” , to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, “Revenue from Contracts with Customers”. which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods therein with a modified retrospective transition. Management is currently evaluating the impact this standard will have on its consolidated financial statements. In July 2017, the FASB issued a two-part ASU 2017-11, “(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception.” The ASU will (1) “change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features” and (2) improve the readability of ASC 480-10 by replacing the indefinite deferral of certain pending content with scope exceptions. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20 “Debt-Debt with Conversion and Other Options”), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that are now pending content in this Codification to a scope exception. Those amendments do not have an accounting effect. This new accounting guidance is effective for public companies for fiscal years beginning after December 15, 2018; however, early adoption is permitted. The Company early adopted the guidance in ASU 2017-11 effective October 1, 2018. In February 2016, the FASB issued ASU 2016-02, “Leases”, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on its consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. ASU 2016-01 provides guidance related to accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. Marketable equity securities previously classified as available-for-sale equity investments are now measured and recorded at fair value with changes in fair value recorded within other expense, net in the Consolidated Statements of Operations rather than as a component of other comprehensive income as in prior years. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The Company adopted this standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In May 2014, the FASB issued Accounting Standards Update ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” which supersedes nearly all existing revenue recognition guidance, including industry-specific guidance. Subsequent to the issuance of ASU No. 2014-09, the FASB clarified the guidance through several Accounting Standards Updates; hereinafter the collection of revenue guidance is referred to as “Topic 606.” Topic 606 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic 606 also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. The Company adopted Topic 606 on January 1, 2018 using the modified retrospective transition method; accordingly, Topic 606 has been applied to the fiscal 2018 financial statements and disclosures going forward, but the comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. Management expects the impact of the adoption of Topic 606 to be immaterial to the Company’s operating results on an ongoing basis. See Note 13, “Revenue Recognition,” for additional details on this implementation and the required disclosures.

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	12 Months Ended
	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, and Short-term Investments	Note 3. Cash, Cash Equivalents and Short-Term Investments Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2018: Carrying Value Cash $ 37,223,698 Cash equivalents: Money market mutual fund 103,427 Total cash and cash equivalents 37,327,125 Short-term investments: U.S. Treasury notes and bills 7,925,975 Mutual funds 2,004,993 Total short-term investments 9,930,968 Cash, cash equivalents and short-term investments $ 47,258,093 Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2018 were as follows: Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. Treasury bills $ 2,948,777 $ 19,523 $ — $ 2,968,300 U.S. Treasury notes 4,953,616 4,059 — 4,957,675 Total available-for-sale investments $ 7,902,393 $ 23,582 $ — $ 7,925,975 The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2018: Amortized Cost Fair Value Due within one year $ 5,913,327 $ 5,936,515 Due between one and two years 1,989,066 1,989,460 Total $ 7,902,393 $ 7,925,975 As of December 31, 2018, there were no available-for-sale investments in an unrealized loss position. The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis, as well as adverse conditions related specifically to the security such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security. During the year ended December 31, 2018, we had no realized gains or losses on available-for-sale investments. Equity Investments We held investments in equity securities with readily determinable fair values of $2.0 million at December 31, 2018. These investments consist of mutual funds that invest primarily in tax free municipal bonds and treasury inflation protected securities. Unrealized gains (losses) during 2018 related to equity securities held at December 31, 2018 are as follows: Net gains (losses) recognized during the year on equity securities $ (16,233 ) Less: net gains (losses) recognized during the year on equity securities sold during the year — Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2018 $ (16,233 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Note 4. Fair Value Measurements We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value. We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values. The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2018 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above: Fair Value Measurements Level 1 Level 2 Level 3 Total December 31, 2018 Cash equivalents: Money market mutual fund $ 103,427 $ — $ — $ 103,427 Marketable equity securities: Mutual funds 2,004,993 — — 2,004,993 Available-for-sale debt securities: U.S. Treasury notes 4,957,675 — — 4,957,675 U.S. Treasury bills 2,968,300 — — 2,968,300 $ 10,034,395 $ — $ — $ 10,034,395 Our equity securities and available-for-sale debt securities, including U.S. treasury notes and U.S. treasury bills, are valued using inputs observable in active markets for identical securities and are therefore classified as Level I within the fair value hierarchy. We did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2018.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories	Note 5. Inventories Inventories consist of the following: December 31, 2018 December 31, 2017 Raw materials $ 123,528 $ 104,745 Finished goods 96,986 10,051 $ 220,514 $ 114,796

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment consist of the following: December 31, 2018 December 31, 2017 Cryogenic shippers and data loggers $ 2,719,973 $ 2,107,642 Furniture and fixtures 148,002 63,411 Capitalized software 545,445 545,445 Computers and software 573,843 519,198 Machinery and equipment 567,506 362,476 Leasehold improvements 1,051,712 436,620 Fixed assets in process 1,374,906 568,688 6,981,387 4,603,480 Less accumulated depreciation and amortization (2,623,889 ) (2,092,306 ) $ 4,357,498 $ 2,511,174 Total depreciation and amortization expense related to property and equipment amounted to $857,900 and $664,800 for the years ended December 31, 2018 and 2017, respectively. The Company leases equipment under capitalized lease obligations with a total cost of $71,000 and accumulated amortization of $6,800 as of December 31, 2018.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 7. Intangible Assets Intangible assets consist of the following: December 31, 2018 Gross Amount Accumulated Amortization Net Amount Weighted Average Amortization Period (years) Patents and trademarks $ 184,595 $ (47,375 ) $ 137,220 — December 31, 2017 Gross Amount Accumulated Amortization Net Amount Weighted Average Amortization Period (years) Patents and trademarks $ 138,021 $ (47,375 ) $ 90,646 — Amortization expense for intangible assets for the years ended December 31, 2018 and 2017 was $0. Estimated amortization expense in calendar year 2019 is expected to be $0.

Accrued Compensation and Relate

Accrued Compensation and Related Expenses	12 Months Ended
	Dec. 31, 2018
Employee-related Liabilities [Abstract]
Accrued Compensation and Related Expenses	Note 8. Accrued Compensation and Related Expenses Accrued compensation and related expenses consist of the following: December 31, 2018 December 31, 2017 Accrued salaries and wages $ 900,797 $ 617,984 Accrued paid time off 361,681 307,530 $ 1,262,478 $ 925,514

Convertible Note

Convertible Note	12 Months Ended
	Dec. 31, 2018
Convertible Notes Payable [Abstract]
Convertible Note	Note 9. Convertible Note On December 14, 2018, we entered into a Securities Purchase and Registration Rights Agreement (the “SPA”) with Petrichor Opportunities Fund I LP (the “Investor”) in connection with (i) the issuance and sale of 1,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Investment Shares”), at a price equal to $10.00 per share (See Note 11) and (ii) the issuance of a $15,000,000 floating rate convertible note (the “Note”) of the Company, with such Note convertible on the terms stated therein into shares of Common Stock (the “Note Shares”) (together, the “Transaction”). In connection with the Transaction, the Company paid Petrichor Opportunities Fund I LP a commitment fee of $250,000 on the aggregate total purchase price for the Transaction. The Note is the senior unsecured obligation of the Company. Unless earlier converted or redeemed, the Note will mature on December 14, 2023. The Note accrues interest at a rate equal to the greater of (a) three-month London Interbank Offered Rate ( ) or (b) two percent, plus the applicable margin of six percent on the outstanding balance of the Notes, payable quarterly on the first business day of each calendar quarter. Prior to the maturity, a holder of the Note will have the right to convert all or any portion of the Note, including any accrued but unpaid interest, into shares of Common Stock at a conversion price of $13.11 per exceeds $17.48 for 15 consecutive trading days and certain additional conditions are satisfied, the Note will automatically convert into shares of Common Stock at the Conversion Price, subject to certain conditions. At any time after June 14, 2019, the Company has the right to redeem all, but not less than all, of the outstanding Note for cash prior to the Maturity Date, at a redemption premium on such amount as follows: (a) prior to December 14, 2019, 112%; (b) after December 14, 2019 but on or prior to December 14, 2020, 109%; and (c) after December 14, 2020, 106% (the “Redemption Premium”). Upon the occurrence of certain events of default as set forth in the Note (other than events of default relating to bankruptcy, insolvency, reorganization or liquidation proceedings) or a change of control, a holder of the Note may require the Company to redeem all or any portion of its Note at the applicable Redemption Premium. If certain events of default relating to bankruptcy, insolvency, reorganization or liquidation proceedings occur, all outstanding principal and accrued and unpaid interest (plus any accrued and unpaid late charges) will automatically become due and payable at the applicable Redemption Premium. The Note contains certain covenants and restrictions, including, among others, that, for so long as the Note is outstanding, the Company will not incur any indebtedness (other than permitted indebtedness under the Note), permit liens on its properties (other that permitted liens under the Note), make payments on junior securities, make dividends or transfer certain assets or permit its unrestricted cash to be less than a minimum amount. Pursuant to the SPA, the Company agreed to register the Investment Shares and the Note Shares by filing a registration statement with the SEC by the 45th calendar day after the closing date of the Transaction. The registration statement was filed on January 28, 2019 and was declared effective by the SEC on February 14, 2019. The issuance costs for this Transaction, including the commitment fee paid to the Investor totaled approximately $480,000. As these costs were incurred to raise both debt and equity, the total costs have been allocated on a pro rata basis to the debt and equity financings based on their relative fair values. The pro-rata portion of these fees related to the Note will be amortized over the five-year stated life of the Note. The interest expense was $66,000 for the year ended December 31, 2018, all of which is included in accounts payable and other accrued expenses in the accompanying consolidated balance sheet as of December 31, 2018.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10. Commitments and Contingencies Facility and Equipment Leases We lease 27,600 square feet of corporate, research and development, and logistics facilities in Irvine, California under an operating lease expiring February 2023, subject to our option to extend the lease for two additional five-year periods. The initial base rent is approximately $24,700 per month. We also lease 8,100 square feet of logistics facilities in Livingston, New Jersey under an operating lease expiring December 2024, subject to our option to extend the lease for an additional five-year period. The initial base rent is approximately $7,600 per month. In addition, we lease 7,600 square feet of logistics facilities in Hoofddorp, The Netherlands under an operating lease expiring May 2023, subject to our option to extend the lease for two additional five-year periods. The initial base rent is approximately $5,400 per month. These lease agreements contain certain scheduled annual rent increases which are accounted for on a straight-line basis. In addition, we lease certain equipment which expires through January 2024. At December 31, 2018, future minimum lease payments are as follows: Years Ending December 31, Operating Leases Capital Leases 2019 $ 525,592 $ 25,940 2020 537,742 25,940 2021 538,893 8,647 2022 542,790 — 2023 198,219 — Thereafter 109,773 — Total minimum lease payments $ 2,453,009 60,527 Amount representing interest at 6% (4,180 ) Present value of future minimum capital lease obligations 56,347 Current portion (23,191 ) $ 33,156 Rent expense for the years ended December 31, 2018 and 2017 was approximately $422,600 and $298,500, respectively. Employment Agreements We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason. Litigation The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. In the opinion of management, there are no legal matters involving the Company that would have a material adverse effect on the Company’s consolidated financial condition or results of operations. Indemnities and Guarantees The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets. The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility and equipment leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities and equipment. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreements.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 11. Stockholders’ Equity Authorized Stock The Company has 100,000,000 authorized shares of common stock with a par value of $0.001 per share, and 2,500,000 undesignated or "blank check" preferred stock, with a par value of $0.001, of which, 800,000 shares have been designated as Class A Convertible Preferred Stock and 585,000 shares have been designated as Class B Convertible Preferred Stock. Common Stock Issuances For Services During the year ended December 31, 2018, 6,228 shares of common stock with a fair value of $70,000 were issued to two members of the board of directors as compensation for services. During the year ended December 31, 2017, 15,872 shares of common stock with a fair value of $70,000 were issued to two members of the board of directors as compensation for services. Petrichor Shares Issued On December 14, 2018, we sold and issued 1,000,000 shares of the Company’s common stock, par value $0.001 per share, at a price equal to $10.00 per share for net proceeds of $9.8 million, and incurred offering costs of $192,000 that were offset against the proceeds. See Note 9 above. August 2018 “At the Market” Equity Offering Program On August 24, 2018, we entered into a sales agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) under which we can sell up to an aggregate offering price of up to $35 million of the Company’s common stock (the “Shares”), from time to time through an “at the market” equity offering program (“ATM Prospectus”). Under the Sales Agreement, the Company will set the parameters for the sale of the Shares, including the number of Shares to be issued, the time period during which sales are requested to be made, the limitation on the number of Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Jefferies, who will act as sales agent, may sell the Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the Shares, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. Jefferies will use its commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, applicable state and federal laws, rules and regulations and the rules of The Nasdaq Stock Market LLC. The Sales Agreement may be terminated by the Company upon ten days’ written notice to Jefferies for any reason. Jefferies may terminate the Sales Agreement upon ten days’ written notice to the Company for any reason or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company. The Sales Agreement provides that Jefferies will be entitled to compensation for its services of 3.0% of the gross sales price of all Shares sold under the Sales Agreement. The Company has no obligation to sell any Shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. The Sales Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and Jefferies, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Sales Agreement were made only for purposes of such agreement and, as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The Shares will be issued pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-215776) (the “Registration Statement”), declared effective by the U.S. Securities and Exchange Commission on February 9, 2017. The Company filed a prospectus supplement with the SEC on August 24, 2018 relating to the offer and sale of the Shares pursuant to the Sales Agreement. During the year ended December 31, 2018, the Company received net proceeds of $3.4 million through the sale of 248,839 February 2018 Tender Offer On February 8, 2018, we completed an exchange offer with respect to the Company’s outstanding warrants to purchase one share of common stock at an exercise price of $3.57 per share (the “Original Warrants”). Through February 2, 2018, we offered holders of the Original Warrants the opportunity to exchange such Original Warrants for an equal number of warrants to purchase one share of common stock at an exercise price of $3.00 per share (the “New Warrants”), conditioned upon the immediate exercise of such New Warrants. Pursuant to the February 2018 Tender Offer, warrants to purchase 1,580,388 shares of the Company’s common stock were tendered by holders of warrants and were amended and exercised in connection therewith, resulting in the issuance by the Company of an aggregate of 1,580,388 shares of its common stock for aggregate gross proceeds of $4.7 million. The Original Warrants were issued (i) in July 2015 in connection with the Company’s registered public offering of 2,090,750 units (each unit consisting of one share of the Company’s common stock and one Original Warrant), and (ii) in January 2016 in connection with the mandatory exchange of all of the Company’s outstanding Class A Convertible Preferred Stock and Class B Convertible Preferred Stock into 4,977,038 units (each unit consisting of one share of the Company’s common stock and one Original Warrant). The terms of the New Warrants included (i) an exercise price of $3.00 per share and (ii) an exercise period that expired concurrently with the expiration of the Offer at 5:00 p.m. (Eastern Time) on February 2, 2018 (the “Expiration Date”). In addition, the shares issuable upon exercise of the New Warrants (the “New Warrant Shares”) were subject to a 60-day lock-up period. The purpose of the Offer was to raise funds to support the Company’s growth plans by providing the holders of the Original Warrants an incentive to exchange their Original Warrants for New Warrants and exercise the New Warrants to purchase shares of the Company’s common stock at a reduced exercise price as compared to the Original Warrants. The Company received all of the proceeds from the immediate exercise of the New Warrants, which will be used by the Company for business growth, including as working capital and for other general corporate purposes. As a result of reducing the exercise price of certain warrants in connection with the February 2018 Tender Offer, a warrant repricing expense of $899,400 was incurred which was determined using the Black-Scholes option pricing model and was calculated as the difference between the fair value of the warrants prior to, and immediately after, the reduction in the exercise price on the date of repricing. Such amount is included in warrant inducement and repricing expense in the consolidated statement of operations for the year ended December 31, 2018. In connection with this offering, the Company incurred $99,400 in offering costs that were offset against the proceeds from this offering. Common Stock Offering On March 31, 2017, we completed an underwritten public offering (the “Offering”) for gross proceeds of $12.7 million for 6,325,000 shares of our common stock (the “Shares”) pursuant to a registration statement on Form S-3 that was previously filed and declared effective by the SEC. The Shares were issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated March 28, 2017, by and among the Company and Cowen and Company, LLC and Needham & Company, LLC, as Representatives of the underwriters, at a public offering price per share of $2.00. The Shares include 825,000 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $11.4 million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this offering, the Company incurred $170,300 in offering costs which were offset against the proceeds from this offering. Supplemental Warrant Exercises In July 2017, the Company received proceeds of $1.8 million from the exercise of 605,114 supplemental warrants which were issued in connection with the October 2016 tender offer. The warrants were exercisable upon issuance and expired on the earlier of (i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company’s common stock equals or exceeded $4.50 for ten consecutive trading days. As of June 27, 2017, the closing price of the Company’s common stock was equal to or exceeded $4.50 for ten consecutive trading days. As a result, the supplemental warrants expiration date was accelerated to July 27, 2017 unless exercised prior to that date. Common Stock Reserved for Future Issuance As of December 31, 2018, approximately 7.8 million shares of common stock were issuable upon exercise of stock options and warrants, as follows: Exercise of stock options 5,757,305 Exercise of warrants 2,049,534 Total shares of common stock reserved for future issuances 7,806,839 In addition, we reserved 1,372,998 shares of common stock issuable upon conversion of our Note, which reflects 120% of the maximum number of Note Shares issuable upon conversion of the Note (See Note 9).

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation Warrants We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on various dates through November 2021. A summary of warrant activity is as follows: Number of Shares Weighted- Average Exercise Price/Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) Outstanding — December 31, 2016 7,447,478 $ 4.29 Issued — — Exercised (1,664,232 ) 3.25 Expired (642,134 ) 8.55 Outstanding — December 31, 2017 5,141,112 $ 4.09 Issued — — Exercised (3,062,739 ) 3.58 Expired (28,839 ) 31.78 Outstanding — December 31, 2018 2,049,534 $ 4.03 1.5 $ 14,563,400 Vested (exercisable) — December 31, 2018 2,049,534 $ 4.03 1.5 $ 14,563,400 (1) Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2018, which was $11.03 per share. The following table summarizes information with respect to warrants outstanding and exercisable at December 31, 2018: Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $ 2.04 70,000 2.3 $ 2.04 70,000 $ 2.04 $ 3.57 1,645,512 1.6 $ 3.57 1,645,512 $ 3.57 $ 6.00 329,734 1.1 $ 6.00 329,734 $ 6.00 $61.20 – $129.60 4,288 0.3 $ 63.58 4,288 $ 63.58 2,049,534 2,049,534 During the year ended December 31, 2018, the Company issued 1,179,784 shares of common stock in connection with the exercise of warrants for proceeds of $4.5 million. In addition, during the year ended December 31, 2018, the Company issued 155,886 shares of common stock in connection with the cashless exercise of warrants to purchase 302,567 shares of common stock. During the year ended December 31, 2017, the Company issued 1,403,149 shares of common stock in connection with the exercise of warrants for proceeds of $4.5 million. In addition, during the year ended December 31, 2017, the Company issued 144,164 shares of common stock in connection with the cashless exercise of warrants to purchase 261,083 shares of common stock. The total intrinsic value of warrants exercised during the years ended December 31, 2018 and 2017 was $21.5 million and $7.1 million, respectively. Stock Options We have five stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), and the 2018 Omnibus Equity Incentive Plan (the “2018 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, the 2011 Plan and the 2015 Plan (the “Prior Plans”) have been superseded by the 2018 Plan. In May 2018, the stockholders approved the 2018 Plan for issuance up to 3,730,179 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2018 Plan. As of December 31, 2018, the Company had 4,114,654 shares available for future awards under the 2018 Plan. During the years ended December 31, 2018 and 2017, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions: December 31, 2018 December 31, 2017 Expected life (years) 5.3 – 7.0 5.3 – 6.6 Risk-free interest rate 2.59% - 3.07 % 1.79% - 2.23 % Volatility 97.7% - 110 % 111% - 115 % Dividend yield 0 % 0 % The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the historical volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future. We recognize stock-based compensation cost over the vesting period using the straight-line single option method. Stock-based compensation expense is recognized only for those awards that ultimately vest. Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following: Year Ended December 31, 2018 2017 Cost of revenues $ 244,239 $ 43,349 General and administrative 3,756,820 2,689,496 Sales and marketing 1,178,115 723,648 Engineering and development 299,451 91,288 $ 5,478,625 $ 3,547,781 A summary of stock option activity is as follows: Number of Shares Weighted- Average Exercise Price/Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) Outstanding — December 31, 2016 4,512,550 $ 4.01 Granted (weighted-average fair value of $3.85 per share) 1,176,300 4.59 Exercised (209,456 ) 3.09 Forfeited (101,199 ) 3.04 Expired (55,337 ) 7.89 Outstanding — December 31, 2017 5,322,858 $ 4.16 Number of Shares Weighted- Average Exercise Price/Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) Granted (weighted-average fair value of $7.78 per share) 1,123,100 9.48 Exercised (445,989 ) 3.38 Forfeited (213,142 ) 6.79 Expired (29,522 ) 5.10 Outstanding — December 31, 2018 5,757,305 $ 5.16 7.2 $ 34,176,300 Vested (exercisable) — December 31, 2018 3,802,043 $ 4.54 6.6 $ 24,688,300 Expected to vest after December 31, 2018 (unexercisable) 1,955,262 $ 6.35 8.4 $ 9,487,900 (1) Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2017, which was $11.03 per share. The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2018: Exercise Price Number Weighted- Weighted- Number Weighted- $1.08 – 2.66 805,858 6.9 $ 1.90 543,558 $ 1.96 $3.00 – 3.44 1,698,159 6.8 $ 3.22 1,146,046 $ 3.19 $4.56 – 4.92 770,891 6.4 $ 4.77 760,392 $ 4.77 $5.00 – 6.65 856,070 6.6 $ 5.04 710,887 $ 5.03 $7.67– 7.89 436,123 6.4 $ 7.80 381,030 $ 7.80 $8.17 – 8.65 737,878 9.2 $ 8.62 142,786 $ 8.62 $9.14 – 22.68 452,326 9.3 $ 10.95 117,344 $ 9.75 5,757,305 3,802,043 As of December 31, 2018, there was unrecognized compensation expense of $9.5 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.8 years. The total intrinsic value of options exercised during the years ended December 31, 2018 and 2017 was $3.7 million and $797,600, respectively.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	Note 13. Revenue Recognition In May 2014, the FASB issued Accounting Standards Update ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” which modifies how all entities recognize revenue. Topic 606 outlines a comprehensive five-step revenue recognition model based on the principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. We adopted Topic 606 on January 1, 2018 using the modified retrospective transition method. The adoption of Topic 606 did not have a material effect on our financial statements or results of operations, and no cumulative catch-up adjustment to the opening balance of retained earnings was required. We used the related practical expedients that allow us to not disclose the transaction price allocated to remaining unsatisfied obligations and an explanation of when we expect to recognize the related revenue. Revenues are recognized when control is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods and services. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. Nature of Goods and Services The Company provides Shippers to its customers and charges a fee in exchange for the use of the Shipper under long-term agreements with customers. The Company’s arrangements convey to the customers the right to use the Shippers over a period of time. The Company retains title to the Shippers and provides its customers the use of the Shipper for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the Shipper is returned to the Company. The vast majority of our revenues are covered under long-term agreements. We have determined that individual Statements of Work (“SOW”), whose terms and conditions taken with a Master Services Agreement (“MSA”), create the Topic 606 contracts which are generally short-term in nature (e.g., 15-day shipping cycle). Our agreements (including SOWs) generally do not have multiple performance obligations and, therefore, do not require an allocation of a single price amongst multiple goods or services. Prices under these agreements are generally fixed. The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is probable. The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered over time and at the time that collectability is probable. The Company also provides short-term logistics and engineering consulting services to some customers, with fees tied to the completion of contractually defined services. We recognize revenue from these services when we satisfy the performance obligation. Revenue Disaggregation The Company operates in one reportable segment and evaluates financial performance on a Company-wide basis. We consider sales disaggregated by end-market to depict how the nature, amount, timing and uncertainty of revenues and cash flows are impacted by changes in economic factors. The following table disaggregates our revenues by major source for the years ended December 31, 2018 and 2017: Years ended December 31, (amounts in thousands) 2018 2017 Biopharmaceutical $ 16,477 $ 9,113 Reproductive medicine 2,173 1,706 Animal health 976 1,135 Total revenues $ 19,626 11,954 Our geographical revenues, by origin, for the years ended December 31, 2018 and 2017, were as follows: Years Ended (amounts in thousands) 2018 2017 Americas $ 17,877 $ 10,638 Europe, the Middle East and Africa (EMEA) 1,365 963 Asia Pacific (APAC) 384 353 $ 19,626 $ 11,954 Performance Obligations At contract inception, an assessment of the goods and services promised in the contracts with customers is performed and a performance obligation is identified for each distinct promise to transfer to the customer a good or service (or bundle of goods or services). To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. Revenue is recognized when our performance obligation has been met. The Company considers control to have transferred upon delivery because the Company has a present right to payment at that time, the Company has transferred use of the asset, and the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the asset. For arrangements under which the Company provides logistics support and management to the customer, the Company satisfies its performance obligations as those services are performed whereby the customer simultaneously receives and consumes the benefits of such services under the agreement. Revenue generated from short-term logistics and engineering consulting services provided to customers is recognized or when the Company satisfies the contractually defined performance obligations. Shipping and handling activities related to contracts with customers are accounted for as costs to fulfill our promise to transfer the associated products pursuant to the accounting policy election allowed under Topic 606. Accordingly, the Company records amounts billed for shipping and handling as a component of revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations. Revenues are recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities. Significant Payment Terms Pursuant to the Company’s contracts with its customers, amounts billed for services or products delivered by the Company are generally due and payable in full within 15 days from the date of the invoice (except for any amounts disputed by the customer in good faith). Accordingly, the Company determined that its contracts with customers do not include extended payment terms or a significant financing component. Variable Consideration In some cases, the nature of the Company’s contracts may give rise to variable consideration, including discounts and allowances or other similar items that generally decrease the transaction price. Variable consideration is estimated at the most likely amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the anticipated performance and all information (historical, current and forecasted) that is reasonably available. Revenues are recorded net of variable consideration, such as discounts and allowances. Warranties The Company’s products and services are provided on an “as is” basis and no warranties are included in the contracts with customers. Also, the Company does not offer separately priced extended warranty or product maintenance contracts. Contract Assets Typically, we invoice the customer and recognize revenue once we have satisfied our performance obligation. Accordingly, our contract assets comprise accounts receivable. Generally, we do not have material amounts of other contract assets since revenue is recognized as control of goods is transferred or as services are performed. Contract Liabilities (Deferred Revenue) Contract liabilities are recorded when cash payments are received in advance of the Company’s performance. Deferred revenue was $66,300 and $73,400 at December 31, 2018 and Practical Expedients and Exemptions We have elected the following practical expedients allowed under Topic 606: · Payment terms with our customers, which are one year or less, are not considered a significant financing component. · Shipping and handling fees and costs incurred in connection with products sold are recorded in cost of sales and are not considered a performance obligation to our customers. · Our performance obligations on our orders are generally satisfied within one year from a given reporting date and, therefore, we omit disclosure of the transaction price allocated to remaining performance obligations on open orders. · The Company expenses incremental direct costs of obtaining a contract (sales commissions) when incurred because the amortization period is generally 12 months or less. The Company does not incur costs to fulfill a customer contract that meet the requirements for capitalization.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes Loss before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 (000’s) United States $ (9,233 ) $ (7,894 ) Foreign (303 ) — $ (9,536 ) $ (7,894 ) The provision for income taxes consists of the following for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 (000’s) Current: Federal $ — $ — State 20 5 Foreign — — Total current expense 20 5 Deferred: Federal 1,167 5,941 State 399 (320 ) Foreign 60 — Change in valuation allowance (1,626 ) (5,621 ) Total deferred expense — — Total provision for income taxes $ 20 $ 5 Significant components of the Company’s deferred tax assets as of December 31, 2018 and 2017 are shown below: December 31, 2018 2017 (000’s) Deferred tax assets: Net operating loss carryforward $ 16,272 $ 15,307 Research credits 167 100 Expenses recognized for granting of options and warrants 2,566 2,014 Accrued expenses and reserves 83 41 Valuation allowance (19,088 ) (17,462 ) $ — $ — Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s income tax provision consists of state minimum taxes. The provision for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows: December 31, 2018 2017 (000’s) Computed tax benefit at federal statutory rate $ (2,002 ) $ (2,684 ) State tax, net of federal benefit (348 ) (277 ) Stock compensation 472 503 Warrant inducement and repricing costs 189 — Permanent items and other 82 56 Tax Cuts and Jobs Act - 8,032 Valuation allowance 1,627 (5,625 ) $ 20 $ 5 At December 31, 2018, the Company has federal and state net operating loss carryforwards of approximately $58,172,000 and $47,329,000 303,000 $107,000 and $91,000, respectively. The Company also has approximately $42,000 of California New Jobs Credits. The federal research tax credit begins to expire in 2026 unless previously utilized and the California research tax credit has no expiration date. The California New Jobs Credit began to expire in 2018. Utilization of the net operating loss and research and development carryforwards might be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. The Company has not completed a study to assess whether an ownership change has occurred. If the Company has experienced an ownership change, utilization of the NOL or R&D credit carryforwards would be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows (in thousands): Federal State December 31, December 31, 2018 2017 2018 2017 Unrecognized tax positions, beginning of period $ 13 $ - $ 11 $ - Gross increase – current period tax positions 15 7 12 7 Gross decrease – prior period tax positions (2 ) - - - Gross increase – prior period tax positions - 6 (1 ) 4 Expiration of statute of limitations - - - - Unrecognized tax positions, end of period $ 26 $ 13 $ 22 $ 11 If recognized, none of the unrecognized tax positions would impact the Company's income tax benefit or effective tax rate as long as the Company's deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company's unrecognized tax positions within the next 12 months. On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act amends the Internal Revenue Code to reduce tax rates and modify policies, credits, and deductions for individuals and businesses. For businesses, the Tax Act reduces the corporate tax rate from a maximum of 35% to a flat 21% rate. The rate reduction is effective on January 1, 2018. As a result of the rate reduction, the Company has reduced the deferred tax asset balance as of December 31, 2017 by $8.0 million. Due to the Company's full valuation allowance position, there was no net impact on the Company's income tax provision at December 31, 2017 as the reduction in the deferred tax asset balance was fully offset by a corresponding decrease in the valuation allowance. In conjunction with the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act, providing one year to gather information for such analyses. As of December 31, 2018, we have completed our assessment of the impact of the Tax Cuts and Jobs Act, and as a result, there were no changes to the provisional amounts recorded as of December 31, 2017.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	Note 15. Subsequent Events The Company has evaluated subsequent events through the filing date of this Annual Report on Form 10-K and determined that no subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto other than discussed in the accompanying notes.

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	Note 16. Quarterly Financial Data (Unaudited) A summary of quarterly financial data is as follows ($ in ‘000’s): Quarter Ended March 31 June 30 September 30 December 31 Year ended December 31, 2018 Total revenues $ 4,023 $ 4,627 $ 5,285 $ 5,691 Gross margin $ 2,184 $ 2,504 $ 2,736 $ 2,816 Loss from operations $ (1,798 ) $ (2,465 ) $ (2,161 ) $ (2,220 ) Net loss $ (2,683 ) $ (2,471 ) $ (2,144 ) $ (2,258 ) Net loss per share - basic and diluted $ (0.10 ) $ (0.09 ) $ (0.07 ) $ (0.08 ) Year ended December 31, 2017 Total revenues $ 2,712 $ 2,917 $ 3,003 $ 3,322 Gross margin $ 1,253 $ 1,393 $ 1,606 $ 1,713 Loss from operations $ (1,769 ) $ (1,864 ) $ (1,988 ) $ (2,271 ) Net loss $ (1,789 ) $ (1,860 ) $ (1,980 ) $ (2,270 ) Net loss per share - basic and diluted $ (0.10 ) $ (0.08 ) $ (0.08 ) $ (0.09 ) Earnings per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the periods shown.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiaries, Cryoport Systems, Inc., Cryoport Netherlands B.V. and Cryoport UK Limited (collectively, the “Company”). All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents Our cash and cash equivalents represent demand deposits, and money market funds which are readily convertible into cash, have maturities of 90 days or less when purchased and are considered highly liquid and easily tradeable.
Short-Term Investments	Short-Term Investments Our investments in equity securities consist of mutual funds with readily determinable fair values which are carried at fair value with changes in fair value recognized in earnings. Investments in debt securities are classified as available-for-sale and are carried at fair value, with unrealized gains and losses, net of tax, reported as accumulated other comprehensive income (loss) and included as a separate component of stockholders’ equity. Gains and losses are recognized when realized. When we have determined that an other than temporary decline in fair value has occurred, the amount related to a credit loss Short-term investments are classified as current assets even though maturities may extend beyond one year because they represent investments of cash available for operations.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, capital lease obligations and the convertible note. The carrying value for all such instruments, except capital lease obligations and the convertible note, approximates fair value at December 31, 2018 and 2017 due to their short-term nature. The carrying value of capital lease obligations approximates fair value because the interest rate approximates market rates available to us for similar obligations with the same maturities. The convertible note bears an interest rate that fluctuates with the changes in LIBOR and, because the variable interest rates approximate market borrowing rates available to us, we believe the $14.7 million carrying value of the convertible note approximates its fair value at December 31, 2018.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2018 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments. Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.
Customers	Customers The Company grants credit to customers within the U.S. and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for a limited number of established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at December 31, 2018, and 2017 are net of reserves for doubtful accounts of $100,000 and $70,000, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates. The Company’s customers are in the biotechnology, pharmaceutical, animal health, reproductive medicine and other life science industries. Consequently, there is a concentration of accounts receivable within these industries, whic h is subject to normal credit risk. As of December 31, 2018, there were two customers that accounted for 29.0% and 23.4%, respectively, of net accounts receivable. There was no other single customer that owed us more than 10% of net accounts receivable at December 31, 2018 and 2017. The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the years ended December 31, 2018 and 2017, the Company had revenues from foreign customers of approximately $1.7 million and $1.3 million, respectively, which constituted approximately 9.0% and 11.1%, respectively, of total revenues. There was one customer that accounted for 18.2% of revenues during the year ended December 31, 2018. No other single customer generated over 10% of revenues during the years ended December 31, 2018 and 2017.
Inventories	Inventories The Company’s inventories consist of packaging materials and accessories that are sold to customers. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.
Property and Equipment	Property and Equipment The Company provides shipping containers (“Shippers”) to its customers and charges a fee in exchange for the use of the Shipper. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the Shipper over a period of time. The Company retains the title to the Shippers and provides its customers the use of the Shipper for a specific shipping cycle. At the culmination of the customer’s shipping cycle, the Shipper is returned to the Company. As a result, the Company classifies the Shippers as property and equipment for the per-use Shipper program. Property and equipment are recorded at cost. Shippers and data loggers, which comprise 34% and 47% of the Company’s net property and equipment balance at December 31, 2018 and 2017, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the consolidated statements of operations.
Capitalized Software	Capitalized Software Capitalized software, which is included in property and equipment, net, consists of costs to develop internal use software, which the Company uses to provide various services to customers. The costs are capitalized from the time that the preliminary project stage is completed and considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Once this software is ready for use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is generally 7 years. Capitalized software is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If an impairment indicator is present, a recoverability analysis is performed based on estimated undiscounted cash flows to be generated form the software in the future. If the analysis indicates that the carrying value is not recoverable from future cash flows, the software cost is written down to the estimated fair value and an impairment is recognized. These estimates are subject to revision as market conditions and the Company’s assessments change.
Intangible Assets	Intangible Assets Intangible assets are comprised of patents and trademarks. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued.
Long-lived Assets	Long-lived Assets If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through December 31, 2018.
Deferred Financing Costs	Deferred Financing Costs Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method, and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings.
Income Taxes	Income Taxes The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ” ASC 740. As of December 31, 2018 and 2017, there were no unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rate. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s provision for income taxes consists of state minimum taxes. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at December 31, 2018 and 2017, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2018 and 2017. The Company is subject to taxation in the U.S., various state jurisdictions, and in the Netherlands. As of December 31, 2018, the Company is no longer subject to U.S. federal examinations for years before 2015 and for California franchise and income tax examinations for years before 2014. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions.
Revenue Recognition	Revenue Recognition See Note 13.
Engineering and Development Expenses	Engineering and Development Expenses Expenditures relating to engineering and development are expensed in the period incurred.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. The Company accounts for forfeitures of unvested awards as they occur. The Company’s stock-based compensation plans are discussed further in Note 12.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of the Company’s common stock for acquiring goods or services are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the estimated fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current estimated fair values at each of those interim financial reporting dates.
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share We calculate basic and diluted net income (loss) per share using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed dividends and cumulative preferred stock dividends (if any), whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average common shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. The following shows the amounts used in computing net loss per share for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 Net loss $ (9,555,601 ) $ (7,899,001 ) Weighted average common shares outstanding – basic and diluted 28,210,648 22,963,382 Basic and diluted net loss per share $ (0.34 ) $ (0.34 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Years Ended December 31, 2018 2017 Stock Options 3,130,635 4,582,383 Warrants 1,329,594 4,579,699 Convertible Note 1,372,998 — 5,833,227 9,162,082
Segment Reporting	Segment Reporting We currently operate in one reportable segment and the chief operating decision maker is our Chief Executive Officer.
Foreign Currency Transactions	Foreign Currency Transactions Management has determined that the functional currency of its subsidiaries is the local currency. Assets and liabilities of the Netherlands and UK subsidiaries are translated into U.S. dollars at the period-end exchange rates. Income and expenses are translated at an average exchange rate for the period and the resulting translation gain (loss) adjustments are accumulated as a separate component of stockholders’ equity. The translation gain (loss) adjustment totaled $(20,400) for the year ended December 31, 2018.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income includes all changes in equity (net assets) during a period from non-owner sources. For the year ended December 31, 2018, the components of comprehensive income (loss) consist of unrealized gains on available-for-sale debt securities and foreign currency translation losses. For the year ended December 31, 2017, net loss equaled comprehensive loss as there were no items of comprehensive loss.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements We do not currently have any off balance sheet arrangements.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified in the consolidated balance sheets to conform to the current year presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting” which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, “Compensation-Stock Compensation ” , to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, “Revenue from Contracts with Customers”. which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods therein with a modified retrospective transition. Management is currently evaluating the impact this standard will have on its consolidated financial statements. In July 2017, the FASB issued a two-part ASU 2017-11, “(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception.” The ASU will (1) “change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features” and (2) improve the readability of ASC 480-10 by replacing the indefinite deferral of certain pending content with scope exceptions. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20 “Debt-Debt with Conversion and Other Options”), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that are now pending content in this Codification to a scope exception. Those amendments do not have an accounting effect. This new accounting guidance is effective for public companies for fiscal years beginning after December 15, 2018; however, early adoption is permitted. The Company early adopted the guidance in ASU 2017-11 effective October 1, 2018. In February 2016, the FASB issued ASU 2016-02, “Leases”, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on its consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments — Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. ASU 2016-01 provides guidance related to accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. Marketable equity securities previously classified as available-for-sale equity investments are now measured and recorded at fair value with changes in fair value recorded within other expense, net in the Consolidated Statements of Operations rather than as a component of other comprehensive income as in prior years. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The Company adopted this standard effective January 1, 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In May 2014, the FASB issued Accounting Standards Update ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” which supersedes nearly all existing revenue recognition guidance, including industry-specific guidance. Subsequent to the issuance of ASU No. 2014-09, the FASB clarified the guidance through several Accounting Standards Updates; hereinafter the collection of revenue guidance is referred to as “Topic 606.” Topic 606 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic 606 also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. The Company adopted Topic 606 on January 1, 2018 using the modified retrospective transition method; accordingly, Topic 606 has been applied to the fiscal 2018 financial statements and disclosures going forward, but the comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. Management expects the impact of the adoption of Topic 606 to be immaterial to the Company’s operating results on an ongoing basis. See Note 13, “Revenue Recognition,” for additional details on this implementation and the required disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Earnings Per Share	The following shows the amounts used in computing net loss per share for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 Net loss $ (9,555,601 ) $ (7,899,001 ) Weighted average common shares outstanding – basic and diluted 28,210,648 22,963,382 Basic and diluted net loss per share $ (0.34 ) $ (0.34 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Years Ended December 31, 2018 2017 Stock Options 3,130,635 4,582,383 Warrants 1,329,594 4,579,699 Convertible Note 1,372,998 — 5,833,227 9,162,082

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents and Investments	Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2018: Carrying Value Cash $ 37,223,698 Cash equivalents: Money market mutual fund 103,427 Total cash and cash equivalents 37,327,125 Short-term investments: U.S. Treasury notes and bills 7,925,975 Mutual funds 2,004,993 Total short-term investments 9,930,968 Cash, cash equivalents and short-term investments $ 47,258,093
Available-for-sale Securities	The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security at December 31, 2018 were as follows: Amortized Cost Unrealized Gains Unrealized Losses Fair Value U.S. Treasury bills $ 2,948,777 $ 19,523 $ — $ 2,968,300 U.S. Treasury notes 4,953,616 4,059 — 4,957,675 Total available-for-sale investments $ 7,902,393 $ 23,582 $ — $ 7,925,975
Investments Classified by Contractual Maturity Date	The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of December 31, 2018: Amortized Cost Fair Value Due within one year $ 5,913,327 $ 5,936,515 Due between one and two years 1,989,066 1,989,460 Total $ 7,902,393 $ 7,925,975
Unrealized Gain (Loss) on Investments	Unrealized gains (losses) during 2018 related to equity securities held at December 31, 2018 are as follows: Net gains (losses) recognized during the year on equity securities $ (16,233 ) Less: net gains (losses) recognized during the year on equity securities sold during the year — Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2018 $ (16,233 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The carrying values of our assets that are required to be measured at fair value on a recurring basis as of December 31, 2018 approximate fair value because of our ability to immediately convert these instruments into cash with minimal expected change in value which are classified in the table below in one of the three categories of the fair value hierarchy described above: Fair Value Measurements Level 1 Level 2 Level 3 Total December 31, 2018 Cash equivalents: Money market mutual fund $ 103,427 $ — $ — $ 103,427 Marketable equity securities: Mutual funds 2,004,993 — — 2,004,993 Available-for-sale debt securities: U.S. Treasury notes 4,957,675 — — 4,957,675 U.S. Treasury bills 2,968,300 — — 2,968,300 $ 10,034,395 $ — $ — $ 10,034,395

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Utility Inventory	Inventories consist of the following: December 31, 2018 December 31, 2017 Raw materials $ 123,528 $ 104,745 Finished goods 96,986 10,051 $ 220,514 $ 114,796

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment consist of the following: December 31, 2018 December 31, 2017 Cryogenic shippers and data loggers $ 2,719,973 $ 2,107,642 Furniture and fixtures 148,002 63,411 Capitalized software 545,445 545,445 Computers and software 573,843 519,198 Machinery and equipment 567,506 362,476 Leasehold improvements 1,051,712 436,620 Fixed assets in process 1,374,906 568,688 6,981,387 4,603,480 Less accumulated depreciation and amortization (2,623,889 ) (2,092,306 ) $ 4,357,498 $ 2,511,174

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets consist of the following: December 31, 2018 Gross Amount Accumulated Amortization Net Amount Weighted Average Amortization Period (years) Patents and trademarks $ 184,595 $ (47,375 ) $ 137,220 — December 31, 2017 Gross Amount Accumulated Amortization Net Amount Weighted Average Amortization Period (years) Patents and trademarks $ 138,021 $ (47,375 ) $ 90,646 —

Accrued Compensation and Rela_2

Accrued Compensation and Related Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Employee-related Liabilities [Abstract]
Schedule of employee related liabilities	Accrued compensation and related expenses consist of the following: December 31, 2018 December 31, 2017 Accrued salaries and wages $ 900,797 $ 617,984 Accrued paid time off 361,681 307,530 $ 1,262,478 $ 925,514

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	At December 31, 2018, future minimum lease payments are as follows: Years Ending December 31, Operating Leases Capital Leases 2019 $ 525,592 $ 25,940 2020 537,742 25,940 2021 538,893 8,647 2022 542,790 — 2023 198,219 — Thereafter 109,773 — Total minimum lease payments $ 2,453,009 60,527 Amount representing interest at 6% (4,180 ) Present value of future minimum capital lease obligations 56,347 Current portion (23,191 ) $ 33,156

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of Common Stock Reserved for Future Issuance	As of December 31, 2018, approximately 7.8 million shares of common stock were issuable upon exercise of stock options and warrants, as follows: Exercise of stock options 5,757,305 Exercise of warrants 2,049,534 Total shares of common stock reserved for future issuances 7,806,839

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Schedule of Warrant Activity	A summary of warrant activity is as follows: Number of Shares Weighted- Average Exercise Price/Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) Outstanding — December 31, 2016 7,447,478 $ 4.29 Issued — — Exercised (1,664,232 ) 3.25 Expired (642,134 ) 8.55 Outstanding — December 31, 2017 5,141,112 $ 4.09 Issued — — Exercised (3,062,739 ) 3.58 Expired (28,839 ) 31.78 Outstanding — December 31, 2018 2,049,534 $ 4.03 1.5 $ 14,563,400 Vested (exercisable) — December 31, 2018 2,049,534 $ 4.03 1.5 $ 14,563,400
Schedule of Fair Value Assumptions of Stock Options	During the years ended December 31, 2018 and 2017, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following assumptions: December 31, 2018 December 31, 2017 Expected life (years) 5.3 – 7.0 5.3 – 6.6 Risk-free interest rate 2.59% - 3.07 % 1.79% - 2.23 % Volatility 97.7% - 110 % 111% - 115 % Dividend yield 0 % 0 %
Schedule of Share-based Payment Awards	Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following: Year Ended December 31, 2018 2017 Cost of revenues $ 244,239 $ 43,349 General and administrative 3,756,820 2,689,496 Sales and marketing 1,178,115 723,648 Engineering and development 299,451 91,288 $ 5,478,625 $ 3,547,781
Schedule of Stock Option Activity	A summary of stock option activity is as follows: Number of Shares Weighted- Average Exercise Price/Share Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) Outstanding — December 31, 2016 4,512,550 $ 4.01 Granted (weighted-average fair value of $3.85 per share) 1,176,300 4.59 Exercised (209,456 ) 3.09 Forfeited (101,199 ) 3.04 Expired (55,337 ) 7.89 Outstanding — December 31, 2017 5,322,858 $ 4.16 Granted (weighted-average fair value of $7.78 per share) 1,123,100 9.48 Exercised (445,989 ) 3.38 Forfeited (213,142 ) 6.79 Expired (29,522 ) 5.10 Outstanding — December 31, 2018 5,757,305 $ 5.16 7.2 $ 34,176,300 Vested (exercisable) — December 31, 2018 3,802,043 $ 4.54 6.6 $ 24,688,300 Expected to vest after December 31, 2018 (unexercisable) 1,955,262 $ 6.35 8.4 $ 9,487,900 (1) Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2017, which was $11.03 per share.
Schedule of Common Stock Reserved for Future Issuance	As of December 31, 2018, approximately 7.8 million shares of common stock were issuable upon exercise of stock options and warrants, as follows: Exercise of stock options 5,757,305 Exercise of warrants 2,049,534 Total shares of common stock reserved for future issuances 7,806,839
Stock Options [Member]
Schedule of Information by Exercise Price Range	The following table summarizes information with respect to stock options outstanding and exercisable at December 31, 2018: Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $ 1.08 – 2.66 805,858 6.9 $ 1.90 543,558 $ 1.96 $ 3.00 – 3.44 1,698,159 6.8 $ 3.22 1,146,046 $ 3.19 $ 4.56 – 4.92 770,891 6.4 $ 4.77 760,392 $ 4.77 $ 5.00 – 6.65 856,070 6.6 $ 5.04 710,887 $ 5.03 $ 7.67– 7.89 436,123 6.4 $ 7.80 381,030 $ 7.80 $ 8.17 – 8.65 737,878 9.2 $ 8.62 142,786 $ 8.62 $ 9.14 – 22.68 452,326 9.3 $ 10.95 117,344 $ 9.75 5,757,305 3,802,043
Warrant [Member]
Schedule of Information by Exercise Price Range	The following table summarizes information with respect to warrants outstanding and exercisable at December 31, 2018: Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $ 2.04 70,000 2.3 $ 2.04 70,000 $ 2.04 $ 3.57 1,645,512 1.6 $ 3.57 1,645,512 $ 3.57 $ 6.00 329,734 1.1 $ 6.00 329,734 $ 6.00 $ 61.20 – $129.60 4,288 0.3 $ 63.58 4,288 $ 63.58 2,049,534 2,049,534

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table disaggregates our revenues by major source for the years ended December 31, 2018 and 2017: Years ended December 31, (amounts in thousands) 2018 2017 Biopharmaceutical $ 16,477 $ 9,113 Reproductive medicine 2,173 1,706 Animal health 976 1,135 Total revenues $ 19,626 11,954
Disaggregation geographical revenues, by origin	Our geographical revenues, by origin, for the years ended December 31, 2018 and 2017, were as follows: Years Ended (amounts in thousands) 2018 2017 Americas $ 17,877 $ 10,638 Europe, the Middle East and Africa (EMEA) 1,365 963 Asia Pacific (APAC) 384 353 $ 19,626 $ 11,954

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Loss before provision for income taxes was attributed to the following jurisdictions for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 (000’s) United States $ (9,233 ) $ (7,894 ) Foreign (303 ) — $ (9,536 ) $ (7,894 )
Schedule of Components of Provision For Income Taxes	The provision for income taxes consists of the following for the years ended December 31, 2018 and 2017: Years Ended December 31, 2018 2017 (000’s) Current: Federal $ — $ — State 20 5 Foreign — — Total current expense 20 5 Deferred: Federal 1,167 5,941 State 399 (320 ) Foreign 60 — Change in valuation allowance (1,626 ) (5,621 ) Total deferred expense — — Total provision for income taxes $ 20 $ 5
Schedule of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2018 and 2017 are shown below: December 31, 2018 2017 (000’s) Deferred tax assets: Net operating loss carryforward $ 16,272 $ 15,307 Research credits 167 100 Expenses recognized for granting of options and warrants 2,566 2,014 Accrued expenses and reserves 83 41 Valuation allowance (19,088 ) (17,462 ) $ — $ —
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes differs from that computed using the federal statutory rate applied to loss before provision for income taxes as follows: December 31, 2018 2017 (000’s) Computed tax benefit at federal statutory rate $ (2,002 ) $ (2,684 ) State tax, net of federal benefit (348 ) (277 ) Stock compensation 472 503 Warrant inducement and repricing costs 189 — Permanent items and other 82 56 Tax Cuts and Jobs Act - 8,032 Valuation allowance 1,627 (5,625 ) $ 20 $ 5
Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns	A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows (in thousands): Federal State December 31, December 31, 2018 2017 2018 2017 Unrecognized tax positions, beginning of period $ 13 $ - $ 11 $ - Gross increase – current period tax positions 15 7 12 7 Gross decrease – prior period tax positions (2 ) - - - Gross increase – prior period tax positions - 6 (1 ) 4 Expiration of statute of limitations - - - - Unrecognized tax positions, end of period $ 26 $ 13 $ 22 $ 11

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	A summary of quarterly financial data is as follows ($ in ‘000’s): Quarter Ended March 31 June 30 September 30 December 31 Year ended December 31, 2018 Total revenues $ 4,023 $ 4,627 $ 5,285 $ 5,691 Gross margin $ 2,184 $ 2,504 $ 2,736 $ 2,816 Loss from operations $ (1,798 ) $ (2,465 ) $ (2,161 ) $ (2,220 ) Net loss $ (2,683 ) $ (2,471 ) $ (2,144 ) $ (2,258 ) Net loss per share - basic and diluted $ (0.10 ) $ (0.09 ) $ (0.07 ) $ (0.08 ) Year ended December 31, 2017 Total revenues $ 2,712 $ 2,917 $ 3,003 $ 3,322 Gross margin $ 1,253 $ 1,393 $ 1,606 $ 1,713 Loss from operations $ (1,769 ) $ (1,864 ) $ (1,988 ) $ (2,271 ) Net loss $ (1,789 ) $ (1,860 ) $ (1,980 ) $ (2,270 ) Net loss per share - basic and diluted $ (0.10 ) $ (0.08 ) $ (0.08 ) $ (0.09 )

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Net loss	$ (2,258,000)	$ (2,144,000)	$ (2,471,000)	$ (2,683,000)	$ (2,270,000)	$ (1,980,000)	$ (1,860,000)	$ (1,789,000)	$ (9,555,601)	$ (7,899,001)
Weighted average common shares outstanding - basic and diluted									28,210,648	22,963,382
Basic and diluted net loss per share	$ (0.08)	$ (0.07)	$ (0.09)	$ (0.10)	$ (0.09)	$ (0.08)	$ (0.08)	$ (0.10)	$ (0.34)	$ (0.34)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,833,227	9,162,082
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,130,635	4,582,383
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,329,594	4,579,699
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,372,998	0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies Additional Information [Line Items]
Convertible Debt, Noncurrent	$ 14,711,580				$ 0				$ 14,711,580	$ 0
Allowance for doubtful accounts receivable	100,000				70,000				100,000	70,000
Revenues	$ 5,691,000	$ 5,285,000	$ 4,627,000	$ 4,023,000	$ 3,322,000	$ 3,003,000	$ 2,917,000	$ 2,712,000	$ 19,626,453	$ 11,954,267
Maturity Period Of Highly Liquid Investments									90 days
Finite-Lived Intangible Asset, Useful Life									7 years
Foreign Currency Transaction Gain (Loss), before Tax									$ (20,400)
Cryogenic Shippers [Member]
Significant Accounting Policies Additional Information [Line Items]
Property Plant Equipment Ownership Percentage	34.00%								34.00%
Data loggers [Member]
Significant Accounting Policies Additional Information [Line Items]
Property Plant Equipment Ownership Percentage					47.00%					47.00%
Foreign Customers [Member]
Significant Accounting Policies Additional Information [Line Items]
Revenues									$ 1,700,000	$ 1,300,000
Accounts Receivable [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									10.00%	10.00%
Accounts Receivable [Member] | Customer One [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									29.00%
Accounts Receivable [Member] | Customer Two [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									23.40%
Sales Revenue, Net [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									10.00%	10.00%
Sales Revenue, Net [Member] | Customer One [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									18.20%
Sales Revenue, Net [Member] | Foreign Customers [Member]
Significant Accounting Policies Additional Information [Line Items]
Concentration risk, percentage									9.00%	11.10%

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Line Items]
Cash	$ 37,223,698
Cash equivalents:
Money market mutual fund	103,427
Total cash and cash equivalents	37,327,125	$ 15,042,189	$ 4,524,529
Short-term investments:
Short-term Investments	9,930,968	$ 0
Cash, cash equivalents and short-term investments	47,258,093
U.S. Treasury notes and bills [Member]
Short-term investments:
Other Short-term Investments	7,925,975
Mutual Funds [Member]
Short-term investments:
Other Short-term Investments	$ 2,004,993

Cash, Cash Equivalents and Sh_4

Cash, Cash Equivalents and Short-Term Investments (Details 1)	Dec. 31, 2018USD ($)
Available-for-sale Securities, Amortized Cost Basis	$ 7,902,393
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	23,582
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Available-for-sale Securities	7,925,975
US Treasury Bill Securities [Member]
Available-for-sale Securities, Amortized Cost Basis	2,948,777
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	19,523
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Available-for-sale Securities	2,968,300
US Treasury Notes Securities [Member]
Available-for-sale Securities, Amortized Cost Basis	4,953,616
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	4,059
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Available-for-sale Securities	$ 4,957,675

Cash, Cash Equivalents and Sh_5

Cash, Cash Equivalents and Short-Term Investments (Details 2)	Dec. 31, 2018USD ($)
Cash and Cash Equivalents [Line Items]
Due within one year, Amortized Cost	$ 5,913,327
Due between one and two years, Amortized Cost	1,989,066
Total, Amortized Cost	7,902,393
Due within one year, Estimated Fair Value	5,936,515
Due between one and two years, Estimated Fair Value	1,989,460
Available-for-sale Securities	$ 7,925,975

Cash, Cash Equivalents and Sh_6

Cash, Cash Equivalents and Short-Term Investments (Details 3)	12 Months Ended
	Dec. 31, 2018USD ($)
Debt and Equity Securities, FV-NI [Line Items]
Net gains (losses) recognized during the year on equity securities	$ (16,233)
Less: net gains (losses) recognized during the year on equity securities sold during the year	0
Unrealized gains (losses) recognized during the year on equity securities still held at December 31, 2018	$ (16,233)

Cash, Cash Equivalents and Sh_7

Cash, Cash Equivalents and Short-Term Investments (Narrative) (Details) $ in Millions	Dec. 31, 2018USD ($)
Equity Securities, FV-NI	$ 2

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Hierarchy) (Details) - Fair Value, Measurements, Recurring [Member]	Dec. 31, 2018USD ($)
Assets, Fair Value Disclosure	$ 10,034,395
Mutual funds
Assets, Fair Value Disclosure	2,004,993
U.S. Treasury notes
Assets, Fair Value Disclosure	4,957,675
U.S. Treasury bills
Assets, Fair Value Disclosure	2,968,300
Money market mutual fund
Assets, Fair Value Disclosure	103,427
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure	10,034,395
Fair Value, Inputs, Level 1 [Member] | Mutual funds
Assets, Fair Value Disclosure	2,004,993
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury notes
Assets, Fair Value Disclosure	4,957,675
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury bills
Assets, Fair Value Disclosure	2,968,300
Fair Value, Inputs, Level 1 [Member] | Money market mutual fund
Assets, Fair Value Disclosure	103,427
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | Mutual funds
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury notes
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury bills
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | Money market mutual fund
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] | Mutual funds
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury notes
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury bills
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] | Money market mutual fund
Assets, Fair Value Disclosure	$ 0

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 123,528	$ 104,745
Finished goods	96,986	10,051
Inventory, Net	$ 220,514	$ 114,796

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cryogenic shippers and data loggers	$ 2,719,973	$ 2,107,642
Furniture and fixtures	148,002	63,411
Capitalized software	545,445	545,445
Computers and software	573,843	519,198
Machinery and equipment	567,506	362,476
Leasehold improvements	1,051,712	436,620
Fixed assets in process	1,374,906	568,688
Property, Plant and Equipment, Gross	6,981,387	4,603,480
Less accumulated depreciation and amortization	(2,623,889)	(2,092,306)
Property, Plant and Equipment, Net	$ 4,357,498	$ 2,511,174

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation	$ 857,900	$ 664,800
Capital Leased Assets, Gross	71,000
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	$ 6,800

Intangible Assets (Schedule of

Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net Amount	$ 137,220	$ 90,646
Weighted Average Amortization Period (years)	7 years
Patents and trademarks [Member]
Gross Amount	$ 184,595	138,021
Accumulated Amortization	(47,375)	(47,375)
Net Amount	$ 137,220	$ 90,646
Weighted Average Amortization Period (years)	0 years	0 years

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Amortization of Intangible Assets	$ 0	$ 0
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 0

Accrued Compensation and Rela_3

Accrued Compensation and Related Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued salaries and wages	$ 900,797	$ 617,984
Accrued paid time off	361,681	307,530
Employee-related Liabilities, Current	$ 1,262,478	$ 925,514

Convertible Note (Narrative) (D

Convertible Note (Narrative) (Details) - USD ($)	Dec. 14, 2020	Dec. 13, 2020	Dec. 14, 2019	Dec. 14, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 14, 2021
Common Stock, Shares, Issued				1,000,000	30,319,038	25,701,924
Common Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001	$ 0.001
Shares Issued, Price Per Share				$ 10
Debt Instrument, Redemption Price, Percentage	106.00%	109.00%	112.00%
Debt Issuance Costs, Net					$ 480,000
Debt Instrument, Convertible, Remaining Discount Amortization Period					5 years
Interest expense					$ (69,253)	$ (15,693)
Petrichor Opportunities Fund [Member]
Debt Instrument, Fee Amount				$ 250,000
Convertible Debt [Member]
Common Stock, Shares, Issued				1,000,000
Common Stock, Par or Stated Value Per Share				$ 0.001
Shares Issued, Price Per Share				$ 10
Stock Issued During Period, Value, Conversion of Convertible Securities				$ 15,000,000
Common Stock, Convertible, Conversion Price, Increase					$ 13.11
Debt Instrument, Convertible, Conversion Price							$ 17.48

Commitments and Contingencies_2

Commitments and Contingencies (Schedule of Future Minimum Lease Payments) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Leases
2019	$ 525,592
2020	537,742
2021	538,893
2022	542,790
2023	198,219
Thereafter	109,773
Total minimum lease payments	2,453,009
Capital Leases
2019	25,940
2020	25,940
2021	8,647
2022	0
2023	0
2024	0
Total minimum lease payments	60,527
Amount representing interest at 6%	(4,180)
Present value of future minimum capital lease obligations	56,347
Current portion	(23,191)	$ 0
Capital Lease Obligations	$ 33,156	$ 0

Commitments and Contingencies_3

Commitments and Contingencies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)ft²	Dec. 31, 2017USD ($)
Property Subject to or Available for Operating Lease [Line Items]
Rental expense	$ 422,600	$ 298,500
Irvine, California Facility [Member]
Property Subject to or Available for Operating Lease [Line Items]
Estimated Base Rent Under Lease	$ 24,700
Lease Expiration Date	Feb. 28, 2023
Land Subject to Ground Leases | ft²	27,600
Livingston [Member]
Property Subject to or Available for Operating Lease [Line Items]
Estimated Base Rent Under Lease	$ 7,600
Lease Expiration Date	Dec. 31, 2024
Land Subject to Ground Leases | ft²	8,100
Hoofddorp [Member]
Property Subject to or Available for Operating Lease [Line Items]
Estimated Base Rent Under Lease	$ 5,400
Lease Expiration Date	May 31, 2023
Land Subject to Ground Leases | ft²	7,600

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details)	Dec. 31, 2018shares
Class of Stock [Line Items]
Common Stock Reserved for Future Issuance	7,806,839
Exercise Of Stock Options [Member]
Class of Stock [Line Items]
Common Stock Reserved for Future Issuance	5,757,305
Exercise Of Warrants [Member]
Class of Stock [Line Items]
Common Stock Reserved for Future Issuance	2,049,534

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Dec. 14, 2018	Feb. 08, 2018	Aug. 24, 2018	Feb. 28, 2018	Jul. 31, 2017	Mar. 31, 2017	Jan. 30, 2016	Jul. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Feb. 02, 2018	Oct. 28, 2016
Class of Stock [Line Items]
Common stock, shares authorized									100,000,000	100,000,000
Common stock, par value	$ 0.001								$ 0.001	$ 0.001
Preferred stock, par value									$ 0.001	$ 0.001
Preferred stock, shares authorized									2,500,000	2,500,000
Stock Issued During Period, Shares, New Issues									248,839
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									302,567	261,083
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 4.50
Common Stock, Capital Shares Reserved for Future Issuance									7,806,839
Stock Issued During Period, Value, New Issues									$ 9,808,330
Proceeds from Issuance of Common Stock	$ 9,800,000								9,808,330	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities							4,977,038
Class Of Warrant Or Right Number Of Warrants Exercised		1,580,388
Shares Issued, Price Per Share	$ 10
Proceeds from Warrant Exercises									$ 6,020,919	$ 5,151,660
Payments of Stock Issuance Costs	$ 192,000
Common Stock, Shares, Issued	1,000,000								30,319,038	25,701,924
Common Stock, Par or Stated Value Per Share	$ 0.001								$ 0.001	$ 0.001
Sale of Stock, Percentage of Ownership before Transaction			3.00%
Other Expenses									$ 44,200
Director [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services									6,228	15,872
Stock Issued During Period, Value, Issued for Services									$ 70,000	$ 70,000
Original Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3.57
Number Of Warrants Issued								2,090,750
Supplemental Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											3
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 3
Proceeds from Warrant Exercises					$ 1,800,000
Class Of Warrant Or Right Exercised Number					605,114
Tender Offer [Member]
Class of Stock [Line Items]
Induced Conversion of Convertible Debt Expense				$ 899,400
Payments of Stock Issuance Costs									$ 99,400
Tender Offer [Member] | Amended [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,580,388
Proceeds from Warrant Exercises		$ 4,700,000
Underwritten Public Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						6,325,000
Stock Issued During Period, Value, New Issues						$ 12,700,000
Proceeds from Issuance of Common Stock						$ 11,400,000
Shares Issued, Price Per Share						$ 2
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued for Services						$ 825,000
Public Offering [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs						$ 170,300
Jefferies [Member]
Class of Stock [Line Items]
Sale Of Stock Market Offering Price			$ 35,000,000
Maximum [Member]
Class of Stock [Line Items]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger									120.00%
Class A convertible preferred stock [Member]
Class of Stock [Line Items]
Preferred stock, par value									$ 0.001	$ 0.001
Preferred stock, shares authorized									800,000	800,000
Class B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized									585,000
Convertible Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued									1,372,998

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Warrant Activity) (Details) - Warrants [Member] - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding		5,141,112	7,447,478
Issued		0	0
Exercised		(3,062,739)	(1,664,232)
Expired		(28,839)	(642,134)
Outstanding		2,049,534	5,141,112
Vested (exercisable)		2,049,534
Weighted-Average Exercise Price/Share
Outstanding		$ 4.09	$ 4.29
Issued		0	0
Exercised		3.58	3.25
Expired		31.78	8.55
Outstanding		4.03	$ 4.09
Vested (exercisable)		$ 4.03
Weighted-Average Remaining Contractual Term (Years)
Outstanding		1 year 6 months
Vested (exercisable)		1 year 6 months
Aggregated Intrinsic Value
Outstanding	[1]	$ 14,563,400
Vested (exercisable)	[1]	$ 14,563,400
[1]	Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the Company’s common stock on December 31, 2018, which was $11.03 per share.

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule of Warrants Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
$ 2.04 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 10 months 24 days
$ 3.57 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 9 months 18 days
$ 6.00 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 7 months 6 days
$61.20 - 129.60 [Member]
Weighted-Average Remaining Contractual Life (Years)	9 years 2 months 12 days
Warrants [Member]
Number Outstanding	2,049,534
Number Exercisable	2,049,534
Warrants [Member] | $ 2.04 [Member]
Number Outstanding	70,000
Weighted-Average Remaining Contractual Life (Years)	2 years 3 months 18 days
Weighted-Average Exercise Price | $ / shares	$ 2.04
Number Exercisable	70,000
Weighted-Average Exercise Price | $ / shares	$ 2.04
Warrants [Member] | $ 3.57 [Member]
Number Outstanding	1,645,512
Weighted-Average Remaining Contractual Life (Years)	1 year 7 months 6 days
Weighted-Average Exercise Price | $ / shares	$ 3.57
Number Exercisable	1,645,512
Weighted-Average Exercise Price | $ / shares	$ 3.57
Warrants [Member] | $ 6.00 [Member]
Number Outstanding	329,734
Weighted-Average Remaining Contractual Life (Years)	1 year 1 month 6 days
Weighted-Average Exercise Price | $ / shares	$ 6
Number Exercisable	329,734
Weighted-Average Exercise Price | $ / shares	$ 6
Warrants [Member] | $61.20 - 129.60 [Member]
Number Outstanding	4,288
Weighted-Average Remaining Contractual Life (Years)	3 months 18 days
Weighted-Average Exercise Price | $ / shares	$ 63.58
Number Exercisable	4,288
Weighted-Average Exercise Price | $ / shares	$ 63.58

Stock-Based Compensation (Sch_2

Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	2.59%	1.79%
Risk-free interest rate, maximum	3.07%	2.23%
Volatility, minimum	97.70%	111.00%
Volatility, maximum	110.00%	115.00%
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	5 years 3 months 18 days	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	7 years	6 years 7 months 6 days

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation	$ 5,478,625	$ 3,547,781
Cost of Revenues [Member]
Share-based Compensation	244,239	43,349
General and Administrative Expense [Member]
Share-based Compensation	3,756,820	2,689,496
Selling and Marketing Expense [Member]
Share-based Compensation	1,178,115	723,648
Engineering And Development [Member]
Share-based Compensation	$ 299,451	$ 91,288

Stock-Based Compensation (Sum_2

Stock-Based Compensation (Summary of Stock Option Activity) (Details) - Stock Options [Member] - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding		5,322,858	4,512,550
Issued		1,123,100	1,176,300
Exercised		(445,989)	(209,456)
Forfeited		(213,142)	(101,199)
Expired		(29,522)	(55,337)
Outstanding		5,757,305	5,322,858
Vested (exercisable)		3,802,043
Expected to vest after (unexercisable)		1,955,262
Weighted-Average Exercise Price/Share
Outstanding		$ 4.16	$ 4.01
Granted		9.48	4.59
Exercised		3.38	3.09
Forfeited		6.79	3.04
Expired		5.10	7.89
Outstanding		5.16	$ 4.16
Vested (exercisable)		4.54
Expected to vest after (unexercisable)		$ 6.35
Weighted-Average Remaining Contractual Term (Years)
Outstanding		7 years 2 months 12 days
Vested (exercisable)		6 years 7 months 6 days
Expected to vest after (unexercisable)		8 years 4 months 24 days
Aggregated Intrinsic Value
Outstanding	[1]	$ 34,176,300
Vested (exercisable)	[1]	24,688,300
Expected to vest after (unexercisable)	[1]	$ 9,487,900
[1]	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on December 31, 2017, which was $11.03 per share.

Stock-Based Compensation (Sch_3

Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
$1.08 - 2.66 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 10 months 24 days
$3.00 - 3.44 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 9 months 18 days
$4.56 - 4.92 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 4 months 24 days
$5.00 - 6.65 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 7 months 6 days
$7.67 - 7.89 [Member]
Weighted-Average Remaining Contractual Life (Years)	6 years 4 months 24 days
$8.17 - 8.65 [Member]
Weighted-Average Remaining Contractual Life (Years)	9 years 2 months 12 days
$9.14 – 22.68 [Member]
Weighted-Average Remaining Contractual Life (Years)	9 years 3 months 18 days
Stock Options [Member]
Number Outstanding	5,757,305
Number Exercisable	3,802,043
Stock Options [Member] | $1.08 - 2.66 [Member]
Number Outstanding	805,858
Weighted-Average Exercise Price | $ / shares	$ 1.90
Number Exercisable	543,558
Weighted-Average Exercise Price | $ / shares	$ 1.96
Stock Options [Member] | $3.00 - 3.44 [Member]
Number Outstanding	1,698,159
Weighted-Average Exercise Price | $ / shares	$ 3.22
Number Exercisable	1,146,046
Weighted-Average Exercise Price | $ / shares	$ 3.19
Stock Options [Member] | $4.56 - 4.92 [Member]
Number Outstanding	770,891
Weighted-Average Exercise Price | $ / shares	$ 4.77
Number Exercisable	760,392
Weighted-Average Exercise Price | $ / shares	$ 4.77
Stock Options [Member] | $5.00 - 6.65 [Member]
Number Outstanding	856,070
Weighted-Average Exercise Price | $ / shares	$ 5.04
Number Exercisable	710,887
Weighted-Average Exercise Price | $ / shares	$ 5.03
Stock Options [Member] | $7.67 - 7.89 [Member]
Number Outstanding	436,123
Weighted-Average Exercise Price | $ / shares	$ 7.80
Number Exercisable	381,030
Weighted-Average Exercise Price | $ / shares	$ 7.80
Stock Options [Member] | $8.17 - 8.65 [Member]
Number Outstanding	737,878
Weighted-Average Exercise Price | $ / shares	$ 8.62
Number Exercisable	142,786
Weighted-Average Exercise Price | $ / shares	$ 8.62
Stock Options [Member] | $9.14 – 22.68 [Member]
Number Outstanding	452,326
Weighted-Average Exercise Price | $ / shares	$ 10.95
Number Exercisable	117,344
Weighted-Average Exercise Price | $ / shares	$ 9.75

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	May 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 3,700,000	$ 797,600
Warrants Exercised Intrinsic Value	$ 21,500,000	$ 7,100,000
Stock Issued During Period Shares Cashless Exercise Of Warrants	155,886	144,164
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	302,567	261,083
Proceeds from Warrant Exercises	$ 6,020,919	$ 5,151,660
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value per share	$ 11.03
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,179,784	1,403,149
Proceeds from Warrant Exercises	$ 4,500,000	$ 4,500,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock options	$ 9,500,000
Weighted average recognition period	2 years 9 months 18 days
Intrinsic value per share		$ 11.03
Plan 2018 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares available for future grant	4,114,654		3,730,179

Revenue Recognition (Disaggrega

Revenue Recognition (Disaggregates Our Revenues by Major Source) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenue Recognition [Line Items]
Revenues	$ 5,691,000	$ 5,285,000	$ 4,627,000	$ 4,023,000	$ 3,322,000	$ 3,003,000	$ 2,917,000	$ 2,712,000	$ 19,626,453	$ 11,954,267
Biopharmaceutical [Member]
Revenue Recognition [Line Items]
Revenues									16,477,000	9,113,000
Reproductive Medicine [Member]
Revenue Recognition [Line Items]
Revenues									2,173,000	1,706,000
Animal Health [Member]
Revenue Recognition [Line Items]
Revenues									$ 976,000	$ 1,135,000

Revenue Recognition (Disaggre_2

Revenue Recognition (Disaggregation our Geographical Revenues, by Origin) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 5,691,000	$ 5,285,000	$ 4,627,000	$ 4,023,000	$ 3,322,000	$ 3,003,000	$ 2,917,000	$ 2,712,000	$ 19,626,453	$ 11,954,267
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenues									17,877,000	10,638,000
Europe, the Middle East and Africa (EMEA) [Member]
Disaggregation of Revenue [Line Items]
Revenues									1,365,000	963,000
Asia Pacific (APAC) [Member]
Disaggregation of Revenue [Line Items]
Revenues									$ 384,000	$ 353,000

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue from Contract with Customer [Abstract]
Deferred Revenue	$ 66,300	$ 73,400
Contract with Customer, Liability, Revenue Recognized	$ 73,400

Income Taxes (Loss Before Provi

Income Taxes (Loss Before Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$ (9,535,647)	$ (7,893,858)
United States
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	(9,233)	(7,894)
Foreign
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$ (303)	$ 0

Income Taxes (Expense For Incom

Income Taxes (Expense For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal	$ 0	$ 0
State	20,000	5,000
Foreign	0	0
Total current expense	20,000	5,000
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]
Federal	1,167,000	5,941,000
State	399,000	(320,000)
Foreign	60,000	0
Change in valuation allowance	(1,626,000)	(5,621,000)
Total deferred expense	0	0
Income Tax Expense (Benefit)	$ 19,954	$ 5,143

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforward	$ 16,272	$ 15,307
Research credits	167	100
Expenses recognized for granting of options and warrants	2,566	2,014
Accrued expenses and reserves	83	41
Valuation allowance	(19,088)	(17,462)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

Income Taxes (Schedule of Incom

Income Taxes (Schedule of Income Tax Provision) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Computed tax benefit at federal statutory rate	$ (2,002,000)	$ (2,684,000)
State tax, net of federal benefit	(348,000)	(277,000)
Stock compensation	472,000	503,000
Warrant inducement and repricing costs	189,000	0
Permanent items and other	82,000	56,000
Tax Cuts and Jobs Act	0	8,032,000
Valuation allowance	(1,626,000)	(5,621,000)
Income Tax Expense (Benefit)	$ 19,954	$ 5,143

Income Taxes (Schedule of unrec

Income Taxes (Schedule of unrecognized tax positions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Domestic Tax Authority [Member]
Unrecognized tax positions, beginning of period	$ 13	$ 0
Gross increase - current period tax positions	15	7
Gross decrease - prior period tax positions	(2)	0
Gross increase - prior period tax positions	0	6
Expiration of statute of limitations	0	0
Unrecognized tax positions, end of period	26	13
State and Local Jurisdiction [Member]
Unrecognized tax positions, beginning of period	11	0
Gross increase - current period tax positions	12	7
Gross decrease - prior period tax positions	0	0
Gross increase - prior period tax positions	(1)	4
Expiration of statute of limitations	0	0
Unrecognized tax positions, end of period	$ 22	$ 11

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 303,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Increase (Decrease) in Deferred Income Taxes		$ 8,000,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$ 42,000
Operating Loss Carryforwards, Percent	80.00%
Scenario, Plan [Member]
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Federal Tax Income [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 3,889,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	58,172,000
Tax Credit Carryforward, Amount	107,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	47,329,000
Tax Credit Carryforward, Amount	$ 91,000

Quarterly Financial Data (Detai

Quarterly Financial Data (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Total revenues	$ 5,691,000	$ 5,285,000	$ 4,627,000	$ 4,023,000	$ 3,322,000	$ 3,003,000	$ 2,917,000	$ 2,712,000	$ 19,626,453	$ 11,954,267
Gross margin	2,816,000	2,736,000	2,504,000	2,184,000	1,713,000	1,606,000	1,393,000	1,253,000	10,240,265	5,966,433
Loss from operations	(2,220,000)	(2,161,000)	(2,465,000)	(1,798,000)	(2,271,000)	(1,988,000)	(1,864,000)	(1,769,000)	(8,644,615)	(7,892,502)
Net loss	$ (2,258,000)	$ (2,144,000)	$ (2,471,000)	$ (2,683,000)	$ (2,270,000)	$ (1,980,000)	$ (1,860,000)	$ (1,789,000)	$ (9,555,601)	$ (7,899,001)
Net loss per share - basic and diluted	$ (0.08)	$ (0.07)	$ (0.09)	$ (0.10)	$ (0.09)	$ (0.08)	$ (0.08)	$ (0.10)	$ (0.34)	$ (0.34)